Novartis survey shows psoriasis patients want treatment effect beyond clear skin
- New patient preference survey confirms that patients value clear skin the most, but expect additional benefits from their treatment, such as proven long-term efficacy and safety data and no injection site reactions[1]
- A separate ranking?incorporating additional?characteristics showed that effectiveness in treating multiple manifestations of psoriatic disease?was also important[1]
- The number of injections per dose and injection frequency were least important to patients according to the ranking analysis[1]
# # #
Novartis Media Relations Central media line: +41 61 324 2200 E-mail: media.relations@novartis.comEric Althoff Novartis Global Media Relations +41 61 324 7999 (direct) +41 79 593 4202 (mobile) eric.althoff@novartis.com | Friedrich von Heyl Novartis Global Pharma Communications +41 61 324 8984 (direct) +41 79 749 0286 (mobile) friedrich.vonheyl@novartis.com |